hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its unaudited interim results for the six-month period ended 30 June 2024.
Financial highlights
• | Revenue of £35.6 million, 30.6% higher than H1 2023 (£27.3 million) |
• | EBITDA up 67.6% to £8.7 million (H1 2023: £5.2 million) |
• | EBITDA margin of 24.5% (H1 2023: 19.1%) |
• | Basic adjusted earnings per share up 30.6% to 0.81p (H1 2023: 0.62p) |
• | Cash of £37.1 million as at 30 June 2024 (H1 2023: £31.3 million) |
• | Weighted contracted orderbook of £71 million as at 30 June 2024 (H1 2023: £78 million) |